Defendant

Celgene Corp.

24 cases as defendant.

Cases
24
Active
15
9 closed
Filed
2015–2025
Top venue
S D N Y
3 cases
Also appears as a plaintiff in 49 cases → View as plaintiff

Company profile

Celgene Corporation (Nasdaq: CELG until 2019) was a biopharmaceutical company headquartered at 86 Morris Avenue, Summit, New Jersey. It was spun off from Celanese in 1986 (some sources cite a 1980 origin) and was acquired by Bristol-Myers Squibb in November 2019 for roughly $74 billion — the largest pharmaceutical acquisition at the time. Celgene now operates as a BMS subsidiary/brand rather than an independent public company; its shares no longer trade. Pre-acquisition, its 2018 revenue was approximately $15.3 billion, with roughly 8,000-plus employees globally.

Products / operations. Celgene discovered, developed, and commercialized therapies for cancer and inflammatory disease. Its principal marketed products were Revlimid (lenalidomide) for multiple myeloma and myelodysplastic syndromes; Pomalyst/Imnovid (pomalidomide) for multiple myeloma; Abraxane (nab-paclitaxel) for several solid tumors; Thalomid (thalidomide); and Otezla (apremilast) for psoriasis/psoriatic arthritis — Otezla was divested to Amgen in 2019 as an antitrust condition of the BMS deal. These brands now sit within BMS's legacy portfolio.

Patent-litigation posture. Celgene is an operating company, not a non-practicing entity, and litigates in both directions. Its 21 plaintiff-side cases are almost entirely Hatch-Waxman/ANDA patent suits against generic filers — Cipla, Dr. Reddy's, Hetero Labs, MSN Laboratories, Apotex, and Hikma — concentrated in the District of New Jersey, its home venue. Its 19 defendant-side cases are predominantly antitrust and pay-for-delay/price-fixing claims brought by health insurers, PBMs, and payers seeking damages related to Revlimid and Thalomid.

Notable cases. In re Revlimid & Thalomid Purchaser Antitrust Litigation (D.N.J., 2019) anchors the defendant-side cluster, alongside suits by Cigna, CenterWell, UnitedHealthcare, Molina Healthcare, Blue Cross Blue Shield, and MSP Recovery Claims. On the plaintiff side, Celgene Corp. v. Cipla and Celgene Corp. v. Dr. Reddy's Laboratories reflect the recurring lenalidomide patent disputes and their Federal Circuit appeals. No cases appear in plaintiff-friendly Eastern District of Texas; the docket is New Jersey- and New York-centric.

Filing activity

2015: 2 cases'15'16'172018: 2 cases'182019: 1 case'192020: 2 cases'202021: 1 case'212022: 1 case'222023: 2 cases'232024: 4 cases4'242025: 3 cases'25
Cases filed per year naming Celgene Corp. as defendant.

The Cigna Group v. Celgene Corp.

active
Docket:
1:25-cv-05237-ER
Filed:
2025-06-24
Patents:8828427

Follow-on antitrust suit alleging Sherman Act § 2 monopolization. Complaint alleges the '427 was expressly taught in prior art and issued after a purportedly false Tutino Declaration, and that Celgene withdrew its '427 infringement claims before most settlements.

CenterWell Pharmacy, Inc. v. Celgene Corp.

pending/consolidated
Court:
S.D.N.Y.
Filed:
2024-09-13
Patents:8735428

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; CenterWell Pharmacy sued Celgene in S.D.N.Y. Status is generally pending/consolidated.

New York Hotel Trades Council & Hotel Ass'n of NYC, Inc., Health Center Inc. v. Celgene Corp.

pending
Docket:
1:24-cv-02230
Filed:
2024-03-25
Patents:8673939

Antitrust/purchaser-overcharge action against Celgene. The '3939 patent is expressly identified in the complaint as part of the alleged monopolization scheme concerning pomalidomide. Case is pending.

Louisiana Health Service & Indemnity Co. (BCBS LA) et al. v. Celgene Corp. et al.

active
Docket:
1:23-cv-07871
Filed:
2023-09-05
Patents:8673939

Antitrust/purchaser-overcharge action alleging monopolization of pomalidomide. The '3939 patent is cited in the complaint as part of the alleged scheme to delay generic entry. Motion to dismiss denied in part; proceeding.

Molina Healthcare, Inc. v. Celgene Corp.

pending/consolidated
Docket:
2:22-cv-04561
Court:
D.N.J.
Filed:
2022-07-13
Patents:8735428

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Molina Healthcare sued Celgene in D.N.J. Status is generally pending/consolidated.

MSP Recovery Claims, Series LLC v. Celgene Corp.

pending/consolidated
Docket:
2:21-cv-20451
Court:
D.N.J.
Filed:
2021-12-10
Patents:8735428

Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; MSP Recovery Claims sued Celgene in D.N.J. Status is generally pending/consolidated.

In re Revlimid & Thalomid Purchaser Antitrust Litigation

pending/consolidated
Docket:
2:19-cv-07532
Filed:
2019-03-01
Patents:8288415

Consolidated purchaser antitrust class action against Celgene concerning Revlimid and Thalomid; US 8,288,415 is cited as a patent-in-suit in the alleged pay-for-delay scheme. No termination date listed.

Humana Inc. v. Celgene Corp.

partially dismissed; amended complaints filed
Docket:
2:19-cv-07532
Patents:7189740

Antitrust follow-on litigation where purchasers/insurers allege Celgene used the '740 and related method-of-treatment patents, serial sham suits, and reverse-payment settlements to delay generic lenalidomide. The court dismissed the insurer and MSP operative complaints on June 6, 2024, with later amended complaints filed.

The Cigna Group v. Celgene Corp.

unknown
Patents:7141018

Later antitrust complaint named alongside other related actions referencing the Thalomid distribution-method patent family and mentioning the '018 patent within the family narrative. The narrative states the '018 patent was not asserted for infringement in this matter.